Under one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its first advice on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just access to this class of drugs.
Per estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The latest guidance affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to universal availability to the injections that can assist patients in reducing considerable body mass, notes the agency.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, according to the WHO.
The advice calls on countries and companies to expand access, by strategies such as voluntary licensing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Drugs Operate
The injections replicate a biological compound to delay gastric emptying, reduce hunger and boost the sense of being full so individuals eat less.
Individuals commonly begin shedding pounds in the initial weeks of commencing the weekly injections.
Evidence suggests users may regain a significant portion after a year of stopping the drug, as their typical food cravings return.
To be above a healthy weight elevates your risk for contracting health problems, like diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the WHO.
